Detalhe da pesquisa
1.
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic.
CA Cancer J Clin
; 70(5): 349-354, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32662880
2.
Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
Breast Cancer Res Treat
; 192(1): 163-173, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022867
3.
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
Breast Cancer Res Treat
; 185(1): 165-173, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32930927
4.
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
Breast Cancer Res Treat
; 189(1): 177-185, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34169393
5.
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
Breast Cancer Res
; 21(1): 52, 2019 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30999962
6.
Facilitating informed decisions about breast cancer screening: development and evaluation of a web-based decision aid for women in their 40s.
BMC Med Inform Decis Mak
; 17(1): 29, 2017 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327125
7.
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
JAMA
; 317(6): 606-614, 2017 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28196257
8.
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
BMC Cancer
; 15: 267, 2015 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25885598
9.
Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
Breast J
; 20(2): 174-9, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24467395
10.
A new paradigm for mechanobiological mechanisms in tumor metastasis.
Semin Cancer Biol
; 22(5-6): 385-95, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22613484
11.
Incremental increase in VEGFR1⺠hematopoietic progenitor cells and VEGFR2⺠endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Breast Cancer Res Treat
; 132(1): 235-42, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22160642
12.
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer.
NPJ Breast Cancer
; 7(1): 108, 2021 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34426581
13.
Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
Fertil Steril
; 113(6): 1251-1260.e1, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32331767
14.
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.
JAMA Dermatol
; 155(6): 724-728, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30840033
15.
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
Clin Breast Cancer
; 8 Suppl 4: S166-70, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19158037
16.
Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus.
Ecancermedicalscience
; 12: 811, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29515652
17.
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
Clin Cancer Res
; 23(3): 666-676, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27769988
18.
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.
Clin Cancer Res
; 23(15): 4066-4076, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28356425
19.
Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer.
Neurooncol Adv
; 3(1): vdab178, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34988456
20.
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
NPJ Breast Cancer
; 2: 16037, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28721390